Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.5.0.2
Liquidity (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2014
Accumulated deficit $ 13,277,814 $ 20,359,446    
Gross proceeds from sale of stock   15,055,841 $ 4,401,799  
Cash and cash equivalents 12,338,275 22,025,007 $ 9,243,153 $ 6,262,445
Cystic Fibrosis Foundation Therapeutics Inc [Member]        
Amount received on milestone payment $ 1,250,000      
Cystic Fibrosis Foundation Therapeutics Inc [Member] | August 2016 [Member]        
Amount received on milestone payment   $ 1,000,000    
Securities Purchase Agreement [Member] | Investors [Member]        
Aggregate common stock sold, shares   5,960,000    
Shares issued price per share   $ 2.50    
Gross proceeds from sale of stock   $ 14,900,000